N-G-yes.

This analytical model assessed, with today’s easy gene sequencing, if upfront next-generation sequencing (NGS) identifying all the popular mutations in metastatic non-small cell lung cancer (NSCLC) could save time and even money than the more conservative specific or reflex testing of genetic alterations. Upfront NGS more than halved the time to results and saved Medicare and Medicaid roughly 1.5 to 2 million dollars per 1 million people at large enrolled. | Pennell, JCO Precis Oncol 2019